Rescue of Infants With MCT8 Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MCT8 Deficiency Caregiver Study

NCT06060197

Monocarboxylate Transporter 8 (MCT8) Deficiency Allan-Herndon-Dudley Syndrome

COMPLETED

Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

NCT05911399

Monocarboxylate Transporter 8 Deficiency Allan-Herndon-Dudley Syndrome

AVAILABLE

Desmopressin for Bedwetting in Children With SCD

NCT04420585

Nocturnal Enuresis Anemia, Sickle Cell

TERMINATED PHASE4

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

NCT02398604

Hypoplastic Left Heart Syndrome

TERMINATED PHASE1

Triac Trial II in MCT8 Deficiency Patients

NCT02396459

Allan-Herndon-Dudley Syndrome

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diiodothyropropionic acid (DITPA)

Drug Administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation.
* Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus.
* Alternatively, the mother or a sister must have a relative with a known MCT8 defect.
* Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency.
* Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.

Exclusion Criteria

• Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated).

Parental decision to terminate the pregnancy.

• Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment.

* Significant cardiac conditions, including:
* Atrial fibrillation or other arrhythmias.
* Unstable angina.
* Coronary heart disease.
* Medications:

Current use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.

• Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.

Maximum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No